Join to view full profile
2500 MetroHealth DriveCleveland, OH 44109
Phone+1 610-609-1894
Dr. Wagner is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. John Wagner is an oncologist in Cleveland OH and is affiliated with Case Western Reserve University. He received his medical degree from Temple University School of Medicine and has been in practice 28 years. He specializes in cellular therapy and hematopoietic stem cell transplantation and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and CAR-T therapy.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1992 - 1995
University of MarylandResidency, Internal Medicine, 1989 - 1992
Lewis Katz School of Medicine at Temple UniversityClass of 1989
Certifications & Licensure
VA State Medical License 2022 - 2028
OH State Medical License 2025 - 2027
WV State Medical License 2023 - 2027
PA State Medical License 1999 - 2026
DE State Medical License 2017 - 2023
NJ State Medical License 2017 - 2023
MD State Medical License 1990 - 1993
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2020-2022
- CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2012-2017
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2012-2017
Clinical Trials
- Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
- Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
- Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Publications & Presentations
PubMed
- Harnessing the Power of Two: High-Dose Stem Cell Haploidentical Transplant in Hematologic Malignancies: A Prospective Trial.Xia Bi, Boula Gattas, Dolores Grosso, Onder Alpdogan, Alicia Bao
Transplantation and Cellular Therapy. 2026-07-03 - Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.Nausheen Ahmed, Alaa Ali, Soyoung Kim, Temitope Oloyede, Matthew Bye
Transplantation and Cellular Therapy. 2026-06-24 - 1 citationsA Tender Reduced-Intensity Conditioning for the Unfit: A Novel 4 Gy Total Body Irradiation-Based Conditioning Followed by Two-Step Haploidentical Stem Cell Transplant,...Xia Bi, Dolores Grosso, Allison Gradone, Joanne Filicko-O'Hara, Kelly A McCorkell
Transplantation and Cellular Therapy. 2024-10-01
Grant Support
- Molecular And Biochemical Analysis Of The Canine MHCNational Center For Research Resources1999–2001
- Molecular And Biochemical Analysis Of The Canine MHCNational Center For Research Resources1997–1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
